&w=3840&q=100)
Storyboard18's Marquee Nights returns - an evening of exclusive candid conversations, creativity, global insights
Storyboard18's 'Marquee Nights' returns on June 2 with an exclusive evening featuring Yannick Bolloré - global media magnate, industry visionary and one of the most influential voices shaping the future of communications read more
May 28, 2025: Storyboard18's Marquee Nights is back - and this time, it promises an evening of sharp ideas and soulful stories. The invite-only series, known for its unplugged conversations with some of the world's most influential minds, returns on June 2 at The Oberoi, Gurgaon with a marquee name in global business, media and marketing: Yannick Bolloré, Chairman and CEO, Havas.
From the future of creativity in an AI-powered world to the evolving business landscape between India and France, this special evening will open a rare window into the mind of one of the most visionary leaders in the global media and communications arena. It's more than a fireside chat - it is a front-row seat to the forces shaping global commerce, culture and content.
STORY CONTINUES BELOW THIS AD
The previous editions have seen the likes of Carl Pei, Read Hastings and William Dalrymple engage in meaningful and impactful conversations on technological innovations, streaming, newest trends in consumer technology, and much more.
More from Business
How Indian fintech startups are driving Malaysia's UPI-like digital payments revolution
Yannick Bolloré
Yannick Bolloré co-founded the production company WY Productions in 2002. In 2006, he joined his family group, the Bolloré Group, to launch and develop its media division. Within five years, Bolloré Média became a leading independent French TV group and was subsequently sold to Canal+, making the Bolloré Group a shareholder in Vivendi.
He then joined Havas in 2011 and became Chief Executive Officer of Havas S.A. in 2013. Upon his arrival, he began an in-depth transformation of the group through the 'Together' strategy, making Havas the most integrated group in the industry. He also orchestrated
the repositioning of the group around the mission 'Make a meaningful difference to brands, businesses and people,' for meaningful, committed and responsible communications.
In June 2024, Bolloré unveiled Havas' new strategic plan, Converged, aiming to supercharge the integration of the group's expertise in creativity, media, production, and technology through a unified operating system. In December 2024, he orchestrated the group's return to the stock market, now listed on Euronext Amsterdam.
STORY CONTINUES BELOW THIS AD
Bolloré was appointed Chairman of the Supervisory Board of Vivendi in April 2018. In connection with the Vivendi Spin-Off, in October 2024, he was appointed Chairman of the Supervisory Board of Canal+ SA and Director of Louis Hachette Group.
Bolloré was named a Young Global Leader in 2008 by the World Economic Forum. He has received numerous honors and awards from international associations and the business press. He is also a Chevalier de l'Ordre des Arts et des Lettres. Bolloré graduated from Paris-Dauphine University in 2001.
So come, be part of a night where ideas are uncorked, perspectives are reshaped and the spotlight is not just on success, but the stories that built it.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
15 minutes ago
- Time of India
Big Fat Legal War Bursts Out aheadof Wegovy Launch
Live Events A high-stakes legal battle has erupted ahead of the anticipated launch of Novo Nordisk 's blockbuster weight-loss drug Wegovy (semaglutide) in India. The Delhi High Court has restrained Dr Reddy's Laboratories (DRL) and OneSource Specialty Pharma from selling semaglutide in the domestic market, following a patent infringement plea by the Danish the court, in an interim order Thursday, has not barred the Indian companies from manufacturing and exporting the drug. 'The defendants have a licence to manufacture the impugned drug, which was granted in December 2024, and have begun manufacturing the drug in April 2025,' noted the order uploaded late added that 'the defendants reserve their right to export the impugned drug in countries where the plaintiff has not been granted a patent yet'.Novo Nordisk on May 26 filed a patent infringement suit against Hyderabad-based Dr Reddy's and contract drugmaker OneSource before the Delhi HC. This was a countermove after Dr Reddy's on May 14 moved the HC seeking revocation of Novo Nordisk's patent for semaglutide— the active ingredient in Wegovy and Ozempic, the Danish firm's popular obesity and diabetes drugs. Novo Nordisk has alleged that Dr Reddy's and OneSource are importing large quantities of semaglutide active pharmaceutical ingredient (API) into India, and using it to manufacture and export violated Novo's patent rights, it claimed.A single-judge bench of the Delhi HC has posted the matter for further hearing on August 19, along with Dr Reddy's patent challenge, a senior lawyer told experts expect Novo Nordisk to appeal the interim order before a division bench as the single bench has not restrained the Indian companies from exporting semaglutide.'Novo Nordisk is taking active steps to protect its inventions in India,' a company spokesperson said. The company said its semaglutide patents are protected in India and it expects continued support and protection of innovation in the country. 'However, we would not like to comment on a sub-judice matter,' the spokesperson a statement to ET, a Dr Reddy's spokesperson said, 'The matter is currently sub judice. We are unable to comment on it at this time.'A spokesperson for OneSource, too, declined comment citing the same a 650-page petition, Novo Nordisk said it became aware of the infringements of its valid patent number IN 262697 in India in October and November 2024.
The Hindu
17 minutes ago
- The Hindu
Champions League trophy has been out of reach for PSG
Billions of dollars have been spent and some of the world's greatest players have come and gone, yet the Champions League trophy has remained agonizingly out of reach for Paris Saint-Germain. That could be about to change The Qatari-owned team is one game away from European club soccer's most prestigious prize, with Inter Milan standing in the way in Saturday's (May 31, 2025) final in Munich. PSG is the favorite, with one of the most exciting teams around, having produced thrilling performances to get past Manchester City and Liverpool. It feels like its time has finally come. But in Inter it faces a wily opponent that is in its second final in three seasons and cut down a rampant Barcelona in an epic semifinal — winning 7-6 on aggregate. The warning signs are there for PSG PSG's run to the final has justified a shift in direction from the bling culture of superstar signings to focus more on young French talent. Owned by Qatar Sports Investments since 2011, PSG signed some of the biggest names in soccer including Zlatan Ibrahimovic, Kylian Mbappe, Neymar and Lionel Messi without ever getting its hands on the trophy it craves most of all. Messi, Neymar and Mbappe have all gone, and without those iconic figures PSG looks a more complete team than ever. But that has come at some cost. Players like Ousmane Dembele, Desire Doue and Khvicha Kvaratskhelia were signed for an estimated $240 million combined in a squad assembled at spectacular expense. Meanwhile, Inter has been savvy in the market — signing older players and picking up free agents to put together a team that has reached two Champions League finals in three years — losing to Man City in 2023 — and won one Italian title in that time. PSG's only previous final was in 2020, a 1-0 loss to Bayern Munich. It was a semifinalist in 2021 and 2024. Elimination in the round of 16 in 2022 and 2023 preceded the decision by president Nasser Al Khelaifi to change his transfer strategy. This year is only the second time since 2011 that three-time champion Inter has advanced beyond the round of 16. Inter last won the Champions League in 2010 under Jose Mourinho. Dembele has been one of the outstanding players in Europe this season with 30 goals in all competitions for PSG, including a run of 24 in 18 games from December to March. Kvaratskhelia was signed from Napoli in January and sparked a turnaround in PSG's fortunes in the Champions League when it looked in danger of being eliminated at the league stage. The Georgian forward was long considered one of the brightest talents in Europe before making the move and has added another dimension to an-already thrilling PSG attack. Midfielders Vitinha and Joao Neves are the engine room, hungrily hunting down the ball when out of possession and springing attacks with the speed of their passing. World Cup winner Lautaro Martinez is Inter's standout player and became the club's all-time leading scorer in the Champions League this season. Defender Denzel Dumfries played a huge role in beating Barcelona with two goals in the first leg at the Nou Camp and goalkeeper Yann Sommer pulled off a string of saves to keep Inter in the tie in the second leg. 'Our opponent, we hold the utmost respect for," Martinez said. 'But with the weapons we've got, we want to hit them where it hurts.' A Champions League winner with Barcelona in 2015, Luis Enrique has won 12 major trophies in spells with the Catalan club and now PSG. If French champion PSG triumphs on Saturday (May 31, 2025) he would become the seventh coach to win the Champions League or European Cup with two different teams. The list includes Carlo Ancelotti, Pep Guardiola and Mourinho. Inter's Simone Inzaghi is hoping to win his first Champions League title at the second time of asking after defeat to City two years ago. Then, as now, Inter was the underdog, and came close to upsetting Guardiola's all-conquering City. 'Matches don't come down to wage bills or turnover, it's the players on the pitch,' Inzaghi said on Friday (May 30, 2025). "We were huge underdogs two years ago and went toe to toe. 'I dreamt of playing the Champions League final. I didn't do it as a player, but thanks to this group of players I've been in two finals as a head coach.' Inzaghi cannot match Enrique's trophy count but has impressed at Inter where he won Serie A last year beside two Italian Cups, his third overall. Only a week ago, Inter surrendered the Serie A title by one point.
Mint
24 minutes ago
- Mint
Temasek backed Cloudnine leads race to acquire ART Fertility for $400 mn
Mumbai: Temasek-backed Cloudnine Hospitals is leading the race to acquire Art Fertility, a UAE-based IVF treatment chain, signalling a growing interest among financial and strategic investors for single-specialty healthcare companies. The deal, valuing Art Fertility at $400 million, has also seen interest from IVI, a European strategic investor, four people with knowledge of the development said on the condition of anonymity. 'The binding bids have come in. There are two final bidders. Cloudnine is likely the frontrunner," the first person cited above said. The deal will give existing investor Gulf Capital an exit. Also read: Temasek, ADIA race to invest up to $300mn in medical equipment firm Micro Life 'Temasek is expected to double down on its investment in Cloudnine to help the company fund the acquisition," the people cited above said. 'The acquisition involves ART Fertility's entire business, comprising Middle Eastern and Indian divisions." Investment bank Moelis & Co. is running the mandate for the transaction. While spokespersons for Temasek and Moelis declined to comment, queries emailed to Cloudnine, ART Fertility and Gulf Capital did not elicit any response. Temasek's new capital infusion comes less than a year after the Singapore government's investment arm bought nearly a 20% stake in Bengaluru-based Cloudnine for around $125 million. The deal, which valued the specialist mother and baby care hospital at around $600 million, gave early-stage venture capital firm Peak XV an exit from the company after 11 years. Founded in 2006 by Dr. R Kishore Kumar, Rohit M.A., M. Ramachandra and Vidya Kumar, Cloudnine is a chain of super-specialty hospitals catering to fertility, maternity care, gynaecology, paediatrics, neonatology, baby care and stem cell banking. Currently, it has 34 centres across Indian cities, including Bengaluru, Delhi, Mumbai, Pune, Chennai, Gurgaon, Ludhiana and Chandigarh. Twelve of the centres are in Bengaluru. Also read: Bain held on to Emcure after the IPO. Here's what's next. ART Fertility was established as an extension to IVI RMA Global, a company focused on assisted reproduction technology (ART), in 2015 under the brand name IVI Middle East. About five years later, Gulf Capital bought IVI RMA's stake and rebranded the company to ART Fertility. For Cloudnine, the acquisition comes at a time when it's realigning its cap table ahead of a public listing that is expected later this year. This would be the hospital chain's second attempt at an initial public offering (IPO). In 2022, it had filed draft papers for a ₹1,200 crore IPO. Cloudnine will leverage ART Fertility's presence in Abu Dhabi, Al Ain and Dubai, alongside 11 clinics across India in cities including Delhi, Chennai, Mumbai and Ahmedabad. Its clinics have seen a swift expansion to become one of the leading players in the Middle East and the Indian subcontinent, with plans to extend services further across the globe, Gulf Capital said in a statement in November 2023. Kids Clinic India Ltd, which operates Cloudnine, reported a consolidated revenue of $145.3 million in FY24 as compared with $119.8 million a year earlier. It narrowed its losses to $3.4 million from a loss of $5.3 million in FY23, according to data from Tracxn. Also read: Dialysis chain NephroPlus engages bankers for a $200-250 mn IPO ICRA noted last year that Kids Clinic will benefit from healthy revenue growth on a steady ramp-up at the existing centres and improving revenue share from new centres. The diversification of its presence across various parts of northern, western and southern India, coupled with plans to set up more units in metros and tier I cities, will also add to its growth. With continuous expansion in recent years resulting in a sizable loss from new centres, its return on capital employed (ROCE) has been low in FY23 and FY24, ICRA said in the note. However, a robust scale of operations, gradual improvement in profit margins of new centres and stable margins of existing areas will support the improvement in ROCE over the medium term, the credit rating firm said.
